导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 20.87% | 369/4773 |
| 近一周 | -0.54% | 1120/5465 |
| 近一月 | -5.33% | 3722/5421 |
| 近一季 | -13.62% | 4174/5231 |
| 近半年 | 16.44% | 359/4920 |
| 近一年 | 27.39% | 282/4394 |
| 近两年 | 157.88% | 198/2954 |
| 近三年 | 124.66% | 71/2253 |
| 成立以来 | 232.07% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.04% 3011/4961 |
62.50% 371/5312 |
- - |
- - |
| 2025 | 58.03% 264/4813 |
-1.53% 2685/3635 |
3.02% 1200/4076 |
54.29% 220/4524 |
0.96% 1634/4813 |
| 2024 | 20.50% 461/3463 |
-1.33% 1213/2808 |
1.85% 438/3014 |
14.99% 1852/3129 |
4.27% 724/3463 |
| 2023 | 1.31% 359/2656 |
20.86% 132/2280 |
-1.03% 437/2385 |
-12.19% 2109/2515 |
-3.55% 720/2655 |
| 2022 | -31.68% 1664/2207 |
-24.42% 1764/1919 |
3.30% 1176/2016 |
-15.89% 1365/2113 |
4.04% 599/2208 |
| 2021 | 10.06% 443/1822 |
-6.17% 983/1255 |
16.38% 205/1330 |
-8.57% 1139/1466 |
10.29% 105/1822 |
| 2020 | 39.34% 336/1250 |
-2.84% 274/1028 |
29.00% 87/1067 |
3.26% 989/1164 |
7.66% 700/1184 |
| 2019 | 61.84% 46/1092 |
43.51% 32/754 |
-11.01% 755/804 |
13.36% 25/850 |
11.80% 45/918 |
| 2018 | -42.42% 616/834 |
- - |
- - |
- - |
-16.18% 628/691 |
| 2017 | 20.73% 177/714 |
- - |
- - |
- - |
- - |
| 2016 | -25.40% 482/605 |
- - |
- - |
- - |
- - |
| 2015 | 55.54% 13/575 |
- - |
- - |
- - |
- - |
| 2014 | 9.95% 208/237 |
- - |
- - |
- - |
- - |
| 2013 | 51.68% 4/186 |
- - |
- - |
- - |
- - |
| 2012 | 2.27% 101/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 招商深证TMT50ETF VS. 长安沪深300非周期A(740101) |